TU Darmstadt / ULB / TUprints

Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics

Bogen, Jan Patrick ; Grzeschik, Julius ; Jakobsen, Jørn ; Bähre, Alexandra ; Hock, Björn ; Kolmar, Harald (2021)
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics.
In: Frontiers in Oncology, 2021, 11
doi: 10.26083/tuprints-00019435
Article, Secondary publication, Publisher's Version

[img]
Preview
Text
fonc-11-672262.pdf
Copyright Information: CC BY 4.0 International - Creative Commons, Attribution.

Download (3MB) | Preview
Item Type: Article
Type of entry: Secondary publication
Title: Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics
Language: English
Date: 3 September 2021
Place of Publication: Darmstadt
Year of primary publication: 2021
Publisher: Frontiers
Journal or Publication Title: Frontiers in Oncology
Volume of the journal: 11
Collation: 25 Seiten
DOI: 10.26083/tuprints-00019435
Corresponding Links:
Origin: Secondary publication via sponsored Golden Open Access
Abstract:

Bladder cancer is a frequent malignancy and has a clinical need for new therapeutic approaches. Antibody and protein technologies came a long way in recent years and new engineering approaches were applied to generate innovative therapeutic entities with novel mechanisms of action. Furthermore, mRNA-based pharmaceuticals recently reached the market and CAR-T cells and viral-based gene therapy remain a major focus of biomedical research. This review focuses on the engineering of biologics, particularly therapeutic antibodies and their application in preclinical development and clinical trials, as well as approved monoclonal antibodies for the treatment of bladder cancer. Besides, newly emerging entities in the realm of bladder cancer like mRNA, gene therapy or cell-based therapeutics are discussed and evaluated. As many discussed molecules exhibit unique mechanisms of action based on innovative protein engineering, they reflect the next generation of cancer drugs. This review will shed light on the engineering strategies applied to develop these next generation treatments and provides deeper insights into their preclinical profiles, clinical stages, and ongoing trials. Furthermore, the distribution and expression of the targeted antigens and the intended mechanisms of action are elucidated.

Status: Publisher's Version
URN: urn:nbn:de:tuda-tuprints-194359
Additional Information:

Keywords: antibody engineering, protein engineering, bladder cancer, urothelial carcinoma, ADC, immunotherapy, immuno-oncology, recombinant viral vector vaccines

Classification DDC: 500 Science and mathematics > 540 Chemistry
600 Technology, medicine, applied sciences > 610 Medicine and health
Divisions: 07 Department of Chemistry > Clemens-Schöpf-Institut > Fachgebiet Biochemie
Date Deposited: 03 Sep 2021 12:31
Last Modified: 14 Nov 2023 19:04
URI: https://tuprints.ulb.tu-darmstadt.de/id/eprint/19435
PPN:
Export:
Actions (login required)
View Item View Item